BR

Active Director Director DIN 10286540
DIN 10286540 First appointment Aug 2023 Primary industry Electrnoics
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2023
Shareholding value •••• Premium profile

About Bibha Rai

Data last updated:

Bibha Rai is a Director at Zenthomed Pharma Private Limited (since 2023). The company operates in Electrnoics. Zenthomed Pharma Private Limited reported revenue of ₹13.1 Lakh (FY 2024).

DIN 10286540
Primary Designation Director
Industry Electrnoics
First Appointment 21 Aug 2023
Oldest Company Age 5 yrs
Largest company Zenthomed Pharma Private Limited · ₹13.1 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Zenthomed Pharma Private Limited U52609MH2021PTC360305
Director21 Aug 20232021₹13.1 Lakh (FY 2024)Active

Board colleagues of Bibha Rai

NameDINCompanyDesignation
Devesh Kumar Rai09172521Zenthomed Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Zenthomed Pharma Private Limited
Premium access

Shareholding and investment profile for Bibha Rai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bibha Rai

Bibha Rai currently holds 1 directorship: Zenthomed Pharma Private Limited (Director, since 21 Aug 2023, revenue ₹13.1 Lakh (FY 2024)).

Bibha Rai was first appointed on 21 Aug 2023 as Director at Zenthomed Pharma Private Limited.

The current boards of Bibha Rai's companies include Devesh Kumar Rai (Zenthomed Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available